COMPANY PRESENTATION NOVEMBER 2016

www.mologen.com

Disclaimer

2

Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this presentation regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities.

Neither this presentation nor the information contained in it may be taken, transmitted or distributed directly or indirectly into or within the United States, its territories or possessions. This presentation is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States of America will be made by means of a prospectus that may be obtained from the issuer and that will contain detailed information about the company and management, as well as financial statements. There will be no public offer of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or South Africa.

This presentation is not for general publication, release or distribution in the United Kingdom and may only be distributed in the United Kingdom to persons who (i) are investment professionals falling within article 19 (5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, in its current version (the “Order”), or (ii) are high net worth entities or other persons to whom it may lawfully be communicated within the meaning of article 49 (2) (a) to (d) of the Order (all such persons will be termed “Relevant Persons” below). Anyone in the United Kingdom who is not a Relevant Person may not act on the basis of this notification release or its contents or rely thereon. Any investment or investment activity to which this notification refers is only available to Relevant Persons and is only carried out with Relevant Persons.

Agenda

3

Business overview and “Next Level“ strategy 4

TLR9 agonist product family: Lefitolimod (MGN1703) 9

Market 14

TLR9 agonist product family: EnanDIM® 17

Key milestones 18

Appendix 19

MOLOGEN summary highlights

4

• New management with clear commercial focus and strong track record of previous successes

• Leading German research player transitioning to global market ready company • Strong value-creative pipeline with lead product lefitolimod in two late-stage

trials & two earlier clinical programs as well as follow-up compounds being qualified for trials in man

Advanced immunotherapy

player

• Lefitolimod has the potential to re-activate the immune system • Monotherapy potential in oncology as well as infectious diseases • Combination therapy potential augmenting other existing effective treatments

Safe & well tolerated lead

product

• mCRC (phase III): sizeable market; immunogenic disease • SCLC (phase II): highly lethal; limited treatment advances; short timelines • Combination treatment in solid tumours (phase I): broad market opportunity

including for collaborations • HIV (phase I): potential to eradicate rather than manage infection

Multi-billion dollar target markets

• Advance clinical development of Lefitolimod • Progress follow-up compounds • Adjust organisation to late stage development needs (esp. manufacturing scale-up) • Propel outlicensing activities

Value-creative milestones ahead

Legend: HIV human immuno-deficiency virus | mCRC metastatic colorectal cancer I SCLC small cell lung cancer

New Executive Board: Clear commercial focus & successful track record

5

Dr. Mariola Söhngen, CEO Walter Miller, CFO

29 years biotech industry and corporate leadership experience as founder and former MOB of Paion

15 key successful out-licensings at Paion across the globe

21 years industry as well as financial expertise from leadership positions at Nuvisan and Santhera Pharmaceuticals AG

Successful IPO of Santhera

• Former MOLOGEN leadership successfully focused on the scientific advancement of the company and its products

• New MOLOGEN management brings long-term experience and is focusing on gearing Mologen towards the commercialisation of its development programs

• Value creating projects are being forcefully pursued and key intellectual capital is being retained

Legend: MOB Member of Board

Next Level Strategy: Transition to commercial enterprise

6

Research driven

Market-facing

History

Focus on basic research • Broad pipeline

comprised of three technology platforms

• Own in-house R&D-scale production (trials fully stocked)

Focus on commercial activities • Pipeline focus on lead

compound & follow-up • Streamlined structure,

operational efficiency • Structured partnering/

licensing activities • US strategy being defined

Harvest lefitolimod potential • Enable commercial-

scale production; transition to CMO

• Focus research on follow-up compounds; transition to CRO

• Reduce headcount while retaining expertise

• Enhance flexibility of cost structure

Today Outlook

“Next Level”

Advanced immunotherapy pipeline: Late-stage lefitolimod & follow-up EnanDIM®

7

Indication(1) PC Ph1 Ph2 Ph3 Timeline(2) Exclusivity(3)

Metastatic colorectal cancer (mCRC)

LPI: ’16/’17 Data: ’19 Filing: ’19/’20

EU: 2030 US: 2028

Small-cell lung cancer (SCLC)

Data: ’17 EU: 2030 US: 2028

Advanced solid malignancies (+ ipilimumab)

LPI: ‘18 Data: ’19

EU: 2036 US: 2036

Human immunodeficiency virus (HIV)

LPI: ‘16 Data: ‘17

EU: 2036 US: 2036

Cancer/ infect. Diseases

Pre-clinical

EU: 2035 US: 2035

Renal cell carcinoma (RCC)

Ph I / II data available On hold

EU: 2036 orphan drug status US: 2038

Lefit

olim

od

Enan

DIM

M

GN

1601

Legend: PC Pre-clinical | PH Phase | LPI last patient in • Notes: (1) Pipeline overview excludes MIDGE platform. | (2) Timeline Denotes latest estimated timeline of upcoming milestones. | (3) Exclusivity Denotes estimated minimum market exclusivity horizon based on patent and data protection

IMPALA (MGN)

IMPULSE (MGN)

TEACH (Aarhus)

MD Anderson

ASET (MGN)

Cancer immunotherapy value proposition: Improve long-term overall survival Traditional chemotherapy Immunotherapy

8 Source: "Immuno-oncology: The new weapon in the war against cancer”, Alistair Campbell; Berenberg Equity Highlights, February 2014. Legend: OS overall survival

Immunotherapy

Control group

time

Patients alive in %

Control group

Chemotherapy

time

Patients alive in %

• Fast effect in many patients • Effect not lasting

• Needs time to be effective • Long-lasting effect in a subgroup

of patients

Immunotherapies target improving OS at the long end of the curve

Safe & well tolerated lead product: “Best in class“ TLR9 agonist

9

• Immunologic activation and good safety profile due to molecular composition

– Safety established in ~400 patients to-date

• High dosing over long periods of time – as required to trigger clinical benefit – possible without major toxic effects

• Clinical strategy optimized for lefitolimod TLR9 activation pattern

Light blue area: Motifs recognized by TLR9 receptor

Lefitolimod is geared to success given its combination of safety & tolerability by design with large potential for clinical benefit

Molecular structure Commentary

Safe & well tolerated lead product: Mechanism of action in oncology

10

• The patient’s immune system generally polices the development of cancer cells − occasionally, cells evade that system, developing into cancer

• Lefitolimod reactivates the patient’s own immune system for anti-cancer surveillance • Lefitolimod can work safely alongside other treatments leveraging the body’s own

immune surveillance system

Legend: mDC myeloid dendritic cell I NK cell natural killer cell I NKT cell natural killer T cell I pDC plasmacytoid dendritic cell

Safe & well tolerated lead product: Mechanism of action in HIV

11

• Patients on ART are cleared from actively infecting HI virus, but T cells keep the virus in its latent stage (no immune response against the virus)

• Lefitolimod as “kick & kill” agent kicks the virus from latency into active infection, and reactivates immune surveillance to kill infected cells by NK cells and CTL

Legend: ART anti-retroviral therapy | HIV human immuno-deficiency virus | pDC plasmacytoid dendritic cell | mDC myeloid dendritic cell | NK cell natural killer cell | CTL cytotoxic T lymphocytes

Safe & well tolerated lead product: Combination therapies represent the next opportunity

12

• Combination treatments aim to combat a disease through various synergistic ways

• Expected to play integral role in future new immunotherapy approaches or breakthrough outcomes

• Increased research – and business development – across the market

• Lefitolimod uniquely positioned as potential “combination partner of choice”

Immunotherapy

Control group

time

Patients alive in %

Combination therapies are the latest advancement in the fight against several global diseases including cancer & HIV

Combination therapies

Combination therapy potential Commentary

Source: "Immuno-oncology: The new weapon in the war against cancer”, Alistair Campbell; Berenberg Equity Highlights, Feb 2014

Multi-billion US$ markets in oncology: Strong fundamentals and significant unmet needs

13

WW Prescription Drugs1 WW Oncology Drugs1

2014 2020

743

987 CAGR +4.8%

2014 2020

79

153 CAGR +11.6%

Colorectal Cancer2 Lung Cancer3 SCLC4

8.3 9.4

2013 2020

CAGR +1.8%

4

13

2010 2020

CAGR +12.5%

0.2

2.3

2014 2024

CAGR +27.7%

• Oncology is expected to be among the largest and fastest growing therapeutic areas worldwide

• Cancer immunotherapies represent a huge market potential: ~US$ 35 bn

Sales in US$ bn

Source: 1EvaluatePharma 2015 | 2ResearchandMarkets Jan 2015 (5 EU, US, Japan & Canada) | 3MarketsandMarkets Nov 2011 (G7 Countries) | 4GlobalData, Jan 2016 (5 EU, US, Japan) | Legend: CAGR Compound Annual Growth Rate

AIDS-related deaths (in million) People living with HIV on ART (in million)

• Better diagnostics • Improved treatment regimens • Price reductions of medicines

• Growing patient population • ART represents no cure • Patients remain infectious

Multi-billion dollar markets in HIV: Increasing number of patients living with HIV

14

<1

17

30

2000 2015 2020

Source: UNAIDS; “Global AIDS Update” (worldwide), 2016 | ART antiretroviral therapy

1.5

1.1

<0.5

2000 2015 2020

• People living with AIDS have opened a market for drugs like Lefitolimod • Eradicating HIV would prevent risks of further transmission and of viremia,

while improving QOL

15

MOLOGEN is developing its lead compound in various directions

Lefitolimod (MGN1703)

• Pivotal multicenter (122) EU (8 countries) study “IMPALA” • Status: started Sep-14 targeting 540 patients • Patient recruitment on track • Aims: to compare OS vs. local gold-standard treatment &

to enable regulatory approval • Targets(1): read-out ~early 2019, filing ~late 2019

mCRC: Phase III

• Multicenter (41) EU (4 countries) study “IMPULSE” • Status: started Mar-14 with recruitment of 100 patients

completed Oct-15 • Aims: to compare OS vs. local gold-standard treatment,

to inform development pathway in SCLC, to further support safety data base

• Target(1): read-out ~early 2017

SCLC: Phase II

• Two-stage single-center (DEN) “TEACH” trial – Aarhus Univ. Hospital

• Status: started Jun-2015 – Stage 1 successfully

completed (15 patients) – Stage 2 first patient Jun-

2016 (target: 15 patients) • Aim: to define value in kick

and kill concept in HIV / infectious diseases

• Target: read out 2017

HIV: Phase I • Single-center (US) proof-of-

concept trial combining lefitolimod with checkpoint inhibitor ipilimumab (Yervoy®) – MD Anderson – 50-60 patients envsiaged

• Status: started Jul 2016 (first patient in)

• Aim: to inform development pathway in combination treatments

• Target: read-out 2019

Solid tumours: Phase I

Multi-billion dollar markets: ongoing clinical trials

Legend: HIV human immune deficiency virus | mCRC metastatic colorectal cancer | SCLC small cell lung cancer Note: (1) Subject to actual overall survival (amongst others).

Legend: EnanDIM® Enantiomeric DNA-based ImmunoModulator | DNA sequence essential for function (so-called “CG motifs”) | new structural feature in EnanDIM providing protection against degradation | phosphorothioate backbone (chemical modification)

Follow-up platform EnanDIM®: Next generation TLR9 agonists

16

• Linear molecules – Simple cost-effective

production • Stability through chemically

modified structure – Usually unfavorable risk /

benefit ratio

Linear DNA-structure

• Stability through closed, dumbbell-shaped structure – Production complexity

• Only natural DNA components – Good safety and

tolerability profile

Lefitolimod EnanDIM®

• Linear molecules; stability through specific feature – Simple cost-effective

production • No chemical modifications

– Good safety and tolerability profile expected

• New family of linear TLR9 agonists, combining safety of molecules containing only natural DNA components with simple production process of linear molecules – Allow drug differentiation on molecular level

• Broad immune activation and anti-tumor effect shown in pre-clinical models • Potential application in cancer and in anti-infective therapies

Near-term Value Inflexion Points: Progress of clinical programs and market readiness

17

Program Inflection point Timeline

mCRC • IMPALA patient recruitment completed ‘16/’17

SCLC • Results of randomized IMPULSE trial ’17

HIV • Results of TEACH trial ’17

Commercial-scale production • Technical transfer of production to third party ’17

Legend: mCRC metastatic colorectal cancer | SCLC Small-cell lung cancer | Timeline Denotes latest estimated timeline of upcoming milestones

Appendix

18

Lefitolimod mechanism of action 20

Lefitolimod ongoing clinical trials overviews 23

Lefitolimod Phase II data mCRC 35

Oncology competitive landscape 40

MGN1601 RCC clinical trial overview 42

Financial information 48

Shareholder structure & IR calendar 50

19

Days Weeks

Innate Cellular

cancer cell

Radiation or Chemotherapy

Adaptive Cellular

B cells

Adaptive Humoral

Weeks to Months

pDC

mDC

monocytes

NK

NKT

ADCC

Lefitolimod (MGN1703)

cytotoxic T lymphocytes

TAA, TSA

Lefitolimod: Oncological mode of action (1/3)

Lefitolimod: Oncological mode of action (2/3) Immune surveillance reactivation (ISR)

20

Lefitolimod: Oncological mode of action (3/3)

21 Legend: ADCC antibody dependent cell-mediated cytotoxicity | BCR B cell receptor | mDC myeloid dendritic cells | MHC Major histocompatibility complex | NK cell natural killer cell | NKT cell natural killer T cell | pDC plasmacytoid dendritic cells | | TAA tumor associated antigens | TCR T cell receptor

mCRC program: phase III (ongoing) pivotal IMPALA study

22

• Primary endpoint overall survival (OS) • Open-label, randomized, controlled, two-arm, multinational phase III trial • 540 patients in around 120 sites in eight European countries, including Top

5 European pharma markets • Biomarkers used as stratification factors: CEA level and NKT activation

PD

Lefitolimod (MGN1703)

Trial Treatment Period

Re-Induction

Induction CT 12–30 weeks

Standard first-line

CT for mCRC

PR/CR Responder

Screening/ Randomization

1:1 Control group PD

Lefitolimod (MGN1703)

with induction CT

Induction CT

PD

Start of 2nd line

PD

Legend: CEA carcinoembryonic antigen - a tumor marker for colorectal cancer | CT chemotherapy | CR complete response | mCRC metastatic colorectal cancer | NKT Natural Killer T cells | PD progressive disease | PR partial response

Maintenance

IMPALA: Inclusion & exclusion criteria

23

PD

Legend: CT computed tomography | ECOG eastern cooperative oncology group | RECIST response evaluation criteria in solid tumors | UICC union for international cancer control

Main inclusion criteria • Histologically confirmed colorectal cancer with unresectable stage IV (UICC) disease (primary

tumor may be present) • Complete or partial response (according to RECIST 1.1), within 12-30 weeks from start of

induction treatment with standard first-line chemotherapy with or without biological agents • ECOG performance status 0 or 1

Main exclusion criteria

• History of other malignant tumors within the last 5 years, except basal cell carcinoma or curatively excised cervical carcinoma in situ

• Known brain metastases (present or treated) • Prior allogenic stem cell transplantation or organ transplantation • Active or uncontrolled infections or undiagnosed febrile condition • Pre-existing autoimmune or antibody mediated diseases or immune deficiency • Inadequate pulmonary function according to the investigator’s judgment, history of interstitial

lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan

IMPALA: Statistical considerations

24 Legend: OS overall survival | w/o without

PD

Median OS comparator

[months]

Median OS treatment [months]

Hazard ratio Events needed [#]

Sample size (w/o drop-

out)

Comments

22 29.5 0.75 365 506 Assumption of 10% drop-out (by month 10 per patient) implies sample size of 540

540 patients planned sample size (270 per arm); 365 events required for analysis • Two-sided stratified log-rank test at a 0.05 significance level • Targeted power for superiority in OS of 1–β = 0.80% with targeted hazard ratio (HR)

of 0.75 Assumptions: • Median OS of 29.5 months from randomization in experimental arm vs. 22 months

from randomization in control group, with the gain in OS deemed clinically relevant • Proportional hazards and exponential distributions • Key variables at α=0.05 and power of 80% (two-sided log-rank) (original protocol

calculation):

IMPALA: Secondary endpoints

25

• Overall survival (OS) from induction start; OS rates • Progression-free survival (PFS) on study treatment, until first

progressive disease (PD), after re-introduction, and after first-line treatment; PFS rates

• Overall response rate (ORR) after randomization • Toxicity and safety profile of lefitolimod (adverse events (AE)) • Quality of Life (QoL) and patient-reported outcomes • Translational research - Immunological analyses of patient samples

during follow-up (e.g. immune cell activation, cytokine levels)

Legend: AE adverse events | ORR overall response rate | OS overall survival | PD oprogressive disease | PFS progression-free survival | QoL quality of life

SCLC program: Phase II (ongoing) randomized IMPULSE study

26

• Primary endpoint overall survival (OS) • Randomized, controlled, two-arm, multinational trial with 100 patients in

Belgium, Austria, Germany and Spain • Biomarkers used as stratification factors: NSE level and NKT activation • Patient enrollment completed

PD

Trial Treatment Period

Maintenance

Induction CT 4 cycles of

platinum-based therapy

Standard first-line CT for extensive disease SCLC

PR/CR Responder

Screening/ Randomization

3:2

Experimental Group: 5th cycle of platinum based CT followed by lefitolimod (MGN1703) maintenance

Control Group: 5th cycle of platinum

based CT followed by local practice

PD

PD

Start of 2nd line

Legend: CR complete response | CT chemotherapy | NKT Natural Killer T cells | NSE neuron specific enolase - a tumor marker for lung cancer | PD progressive disease | PR partial response | SCLC small cell lung cancer

IMPULSE: Main inclusion and exclusion criteria

27 Legend: CR complete response | CT chemotherapy | NKT Natural Killer T cells | NSE neuron specific enolase - a tumor marker for lung cancer | PD progressive disease | PR partial response | SCLC small cell lung cancer | ECOG eastern cooperative oncology group

Main inclusion criteria • Extensive disease SCLC confirmed by a pathologist, on the basis of histology of SCLC

or mixed histology of SCLC, or a cytological diagnosis if histology cannot be obtained • Completion of 4 cycles of first-line therapy with a platinum-based regimen and no other

prior chemotherapy • Documented evidence of tumor response (PR or CR) as assessed by the investigator at

the end of the fourth cycle of platinum-based first-line chemotherapy using CT or magnetic resonance imaging (MRI) scan

• ECOG performance status 0 or 1 Main exclusion criteria • Prior or current other malignancy, except adequately treated superficial bladder cancer,

basal or squamous cell carcinoma of the skin, or other cancer for which the patient has been disease free for more than 3 years

• History of carcinomatous meningitis • Prior or current paraneoplastic syndrome related to SCLC • History of autoimmune disease or immune deficiency

IMPULSE: Secondary endpoints

28

PD

Legend: OS overall survival | PFS progression-free survival | RECIST response evaluation in solid tumors | irRC immune-related response criteria | AEs adverse events

Efficacy • OS from the start of the first cycle of induction chemotherapy (OS1) • Progression-free survival (PFS) from the date of randomization with progression

assessed by response evaluation in solid tumors (RECIST) 1.1 and immune-related response criteria (irRC)

• PFS from the start of the first cycle of induction chemotherapy (PFS1) assessed by RECIST 1.1 and irRC

• Best objective response rate (ORR) with clinical response assessed by RECIST 1.1 and irRC

• Quality of life measured by Lung Cancer Symptom Scale at every staging • Treatment outcome correlation of predefined biomarkers and immune parameters Safety • Safety profile of MGN1703 in terms of the incidence of adverse events (AEs) graded

according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC Version 4.03)

• Autoimmunity of MGN1703 in terms of antinuclear antibodies

29 Legend: SCLC small cell lung cancer | HR hazard ratio | mOS median overall survival | vs versus

• Patients with extensive disease SCLC after response to platinum-based chemotherapy are expected to have a median OS of about 9 months with currently available treatment options

• 100 patients • The number of events observed after an additional follow-up of 12 months will have the

power to detect a difference between the 2 treatment arms according to the following table (1-sided alpha of 0.025):

IMPULSE: Statistical considerations

Safe & well tolerated lead product: Mode of action in HIV

30

• Patients on ART carry the HI virus which is suppressed by the therapy and invisible to the immune system (latent infected cells)

• Lefitolimod “kick & kill” approach triggers viral particles to “unhide” so they can be eradicated by the immune system which is also activated by lefitolimod

KICK via latency reversal

KILL via anti-retroviral therapy

KILL via activated cells

(NK/CD8)

KICK via immunomodulation (activation of pDC)

Legend: LRA latency-reversal agent | ART anti-retroviral therapy | NK cell natural killer cell I pDC plasmacytoid dendritic cell

31

• Collaboration agreement with Aarhus University Hospital, DK • First trial of lefitolimod (MGN1703) in HIV patients • Aarhus University Hospital conducts the trial; MOLOGEN provides

lefitolimod (MGN1703); funding received from the American Foundation for AIDS research (amFAR)

• Extension phase: More patients to be treated for 6 months based on broad activation of immune system induced by lefitolimod as shown in first phase – Activation of plasmacytoid dendritic cells (pDC), natural killer cells (NK)

and T cells in HIV patients during the antiretroviral therapy (ART) – Lefitolimod (MGN1703) could play a role in “kick &and kill‘‘ concept of

HIV eradications – First patients of extension phase enrolled

• Final results expected in mid-2017

HIV program: Phase I (ongoing)

The HIV program explores potential expansion of applications of lefitolimod (MGN1703)

Legend: ART antiretroviral therapy | HIV human immuno-deficiency virus | NK cells natural killer cells| pDC plasmacytoid dendritic cells

Combination program: Phase I (ongoing) lefitolimod (MGN1703) and ipilimumab (Yervoy®)

32

• Collaboration with MD Anderson Cancer Center, Texas, US • First combination trial of lefitolimod (MGN1703) with checkpoint inhibitor,

commercially available ipilimumab (Yervoy®), manufactured by Bristol-Myers Squibb Co.

• MD Anderson Cancer Center conducts the trial; MOLOGEN provides lefitolimod (MGN1703) and funding for the trial

• Phase I trial in 50-60 patients with advanced solid malignancies, mainly melanoma

The combination program explores further potential expansion of applications of lefitolimod (MGN1703)

Study outline • Open-label, single site, phase I trial • Patients with advanced solid tumors • Primary endpoints: Safety, toxicity, MTD, and DLTs of combination therapy; dose finding for phase 2 • Dose escalation part followed by three expansion cohorts:

• Dose escalation: Six lefitolimod dose levels (3.75 – 120 mg) with up to 6 patients per dose level to find MTD; • Once MTD is determined, patients will be enrolled in three expansion cohorts (5-12 patients each) at this dose to further

define this dose and to help determine biological endpoints. • Expansion Cohorts (Malignancy / Variable): (1) Melanoma / lefitolimod SC; (2) Melanoma / lefitolimod IT; (3) Advanced

malignant diseases / recent radiation to tumor

Treatment Course • Lefitolimod (MGN1703) administered weekly, SC (dose escalation and 2 expansion cohorts) or IT (one expansion cohort) • ipilimumab always administered at 3mg/kg IV every 3 weeks • Patients will receive treatment for 4 cycles – a total of 12 weeks • Treatment will be discontinued in case of disease progression • If patients demonstrate stable disease or a response, they will be eligible to continue to receive lefitolimod for up to a year

33

Combination trial: Lefitolimod (MGN1703) and ipilimumab (Yervoy®)

Legend: MTD maximum tolerated dose | DLT dose limiting toxicities | SC subcutaneous | IT intratumoral | IV intravenous

mCRC program: Phase II (completed) IMPACT study design

34

Trial Treatment Period

*at investigators’ discretion

Maintenance

Induction CT 4.5-6 months

mCRC patients treated first-line with FOLFOX /

XELOX or FOLFIRI +/- bevacizumab*

At least SD

Experimental Group: 60mg lefitolimod (MGN1703)

twice weekly s.c.

No maintenance Placebo

Twice weekly s.c.

Screening / Randomization

2:1

PD**

PD**

** Treatment after PD at investigators’ discretion

• Primary endpoint: progression-free survival • Double-blind, randomized, placebo-controlled, two-arm, multinational phase

II trial with 59 mCRC patients • Start: June 2010 • Primary completion date: February 2013

Legend: CEA carcinoembryonic antigen - a tumor marker for colorectal cancer | CT chemotherapy | mCRC metastatic colorectal cancer | NKT natural killer T cells | PD progressive disease | s.c. subcutaneous injection | SD stable disease

mCRC program: Phase II (completed) primary endpoint suggests efficacy

35

• PFS from start of maintenance (local assessment)

• ~ 10% long-term responders

Legend: CI confidence interval | HR hazard ratio | mPFS median progression-free survival

Final results MARCH 2013

4 progression-free patients still on treatment at end of study

MGN1703 (n=43)

Placebo (n=16)

mPFS [95% CI]

2.8 months [2.8-4.1]

2.6 months [2.5-2.8]

HR=0.55 [95% CI: 0.3-1.0]

mCRC program: Phase II (completed) IMPACT key take-aways (1/2)

36

• Primary endpoint met:

– progression free survival (HR 0.55, p= 0.04)

• Secondary endpoint “Overall Survival“:

– median OS 22.6 months (lefitolimod (MGN1703)) vs. 15.1 months (p=ns),

– in subgroup (relevant patients for phase III: responders (PR, CR) to induction

chemotherapy):

median OS 24.5 months (lefitolimod (MGN1703)) vs. 15.1 months (p=0.069)

• Predictive biomarkers identified:

– tumor reduction by induction therapy

– normalized CEA level

– presence of activated NKTs

Legend: CEA carcinoembryonic antigen - a tumor marker for colorectal cancer | HR Hazard Ratio | NKT Natural Killer T cells | ns not significant

mCRC program: Phase II (completed) IMPACT key take-aways (2/2)

37

• Long-term treatment with lefitolimod

– Follow-up of four patients who continued MGN1703 monotherapy in

compassionate use programs since no relapse at end of study:

• 3 patients progression-free in excess of 58 months as of June 2016

• Excellent safety and tolerability, also when treated long-term

Legend: CEA carcinoembryonic antigen - a tumor marker for colorectal cancer | HR Hazard Ratio | NKT Natural Killer T cells | ns not significant

Findings from subgroup analyses were used to optimize the phase III study design

mCRC program: Phase II (completed) IMPACT sustained efficacy

38

April 2010: Patient 049 – Initial diagnosis • Colon carcinoma with multiple liver metastases December 2010: After induction chemotherapy • 06/2010 - 11/2010: 9 courses of CT (FOLFIRI) +

bevacizumab (biologic) • 12/2010: Response to induction CT: PR*

March 2015: Under maintenance therapy • Since 12/2010: Lefitolimod (MGN1703) maintenance

therapy • New PR(1) after 9 months • Still ongoing PR • Good medical condition, mild local skin reactions, no

further severe toxicities

Legend: CT chemotherapy | PR partial response • Note: (1) Confirmed by two independent radiologists.

Competitive landscape oncology (1)

39 Note: (1) Mostly in mCRC; limited competing developments in SCLC Legend: mCRC metastatic colorectal cancer I SCLC small cell lung cancer I Mab monoclonal antibodies

Today

mCRC SCLC

• Chemotherapy (FOLFOX, FOLFIRI) + biologicals (“Mab”: anti-VGEF or anti-EGFR)

• Chemotherapy

Future

Various approaches in trials (examples)1

• Checkpoint inhibitors (CTLA4, PD1, PD-L1, …)

• TLR agonists • Cell therapies • Vaccines (tumor cell or antigen

based)

Indication-specific competition first-line mCRC & SCLC

Lefitolimod has potential to differentiate by long-term efficacy, good tolerability, and high safety

Competitive landscape oncology (2)

40

Pharmaceutical class competition, TLR9 agonists across indications:

• Lefitolimod is the sole TLR9 agonist in phase III development in oncology

– Dynavax, US: SD-101, phase II NHL & phase II melanoma

– Idera, US: IMO-2125, phase II melanoma

– Oligovax, France: Litenimod, phase II glioblastoma multiforme

– Innate, France: MIS416, phase II MS; oncology indications preclinical

– Checkmate, US: CMP-001, phase I melanoma

• Index, Sweden: Kappaproct, the sole other TLR9 in phase III development across indications, however in ulcerative colitis with no disclosed development in oncology

– BiolineRX, Israel: BL-7040 is in phase II against ulcerative colitis & in phase II

against IBD

Source: EvaluatePharma, company websites, Aug 2016 I NHL non-Hodgking’s lymphoma

MGN1601: Therapeutic cancer vaccine: Shipped off the shelf

41

MGN1601: Cell-based cancer vaccination available off the shelf

42

Either single or small number of tumor antigens as peptides, loaded dendritic cells, or clonally selected cell lines; HLA-restricted response selects against tumors not expressing the antigen(s), and thereby driving immune evasion of the tumor

Introduced tumor antigens may not be processed & presented in a natural way

Long and challenging manufacturing process of autologous approaches, individually for each patient

Only moderately immunogenic vaccines (clonal tumor cells, “loaded” dendritic cells), lacking sufficient co-stimulatory signals, use of weak adjuvants

Improved properties to conventional cell-based cancer vaccination strategies

Not clonally selected, allogeneic tumor cell line presents an abundance of broadly recognized key tumor antigens, thereby preventing immune evasion

Unique, allogeneic tumor cell line with naturally processed and presented antigens

GMP-production process in place, batch production and storage established, off the shelf shipment

First 4-fold gene-modified cell-based vaccine expressing co-stimulators (CD80, CD40L) and cytokines, (GM-CSF, IL-7) to enhance immune recognition, potent TLR9 agonist reactivates immune surveillance

Limitations of previous cell-based cancer vaccines

Solution provided by the MGN1601 tumor vaccine

ASET Trial with MGN1601: Promising data

43

Phase I/II study (12/2010 – 08/2013) • Open-label, proof-of-principle, multi-center phase I/II trail • 19 patients with advanced renal cell carcinoma who failed prior systemic

therapies • Primary endpoint met: Favorable safety and tolerability profile • Promising overall survival data in subgroup of patients • Improved function in patient‘s immune cells • Identification of potential biomarkers

ASET trial with MGN1601: Study design

44

TPP Extension phase

Patients with

advanced renal cell cancer

No standard therapy

available

Trial inclusion

8 applications of MGN1601

in 12 weeks i.d.

DC Max. 5

applications in week 24, 36, 48,

72 and 120

Trial Treatment Period

SD PD**

PD**

** Treatment after PD at investigators discretion 8 applications

of MGN1601 in 12

weeks i.d.

• Primary endpoints met: safety and tolerability • Open-label, proof-of-principle, multi-center phase I/II trial • 19 patients with advanced renal cell carcinoma who failed prior systemic therapies • Orphan drug designation from EMA • Start: December 2010 – primary completion date: August 2013

Legend: SD Stable disease | EMA European Medicines Agency | i.d. intradermal injection | PD progressive disease | TPP Treatment per protocol

ASET trial with MGN1601: Study results (1/2)

45

• Overall survival benefit – ITT group (19 patients): all patients who received at least one vaccination – PP group (10 patients): patients received eight vaccinations within twelve weeks

as planned – Non-PP group (9 patients): patients dropped out before finalizing the 12 weeks

course of treatment

Legend: ITT intent-to-treat | OS overall survival | PP (treatment) per-protocol

46

• Median OS: – 24.8 weeks (ITT group) vs. 115.3 weeks (PP group)

• Potential biomarker identified: – MSKCC Score & NLR may have predictive value for longer overall survival (OS) – First evidence of cytotoxic antitumor immune response after MGN1601

vaccination (in patient subgroup) – Significant improvement of cellular immune function during treatment (in patient

subgroup) • Two patients had no progression after 12 weeks and continued treatment:

– One patient with stable disease progressed after 48 weeks – One patient had sustained partial response for over 120 weeks

ASET trial with MGN1601: Study results (2/2)

Legend: MSKCC Memorial Sloan–Kettering Cancer Center | NLR neutrophil-lymphocyte ratio | OS overall survival

Shares

47

• ISIN DE0006637200 • Shares issued: 33,947,251 • Market capitalization ~ €50 m (November 2016) • Frankfurt Stock Exchange (Prime Standard): MGN I Reuters: MGN.DE

29%

5% 4%

4% 3%

55%

Global Derivative Trading GmbH

Deutsche Balaton Aktiengesellschaft

Baloise Holding AG

Deutscher Ring Krankenversicherungsverein a.G.

IPConcept (Luxemburg) S.A.

Freefloat

IMPULSE Start Primary analyses (OS)

BIO-Europe 2016, Cologne

Upcoming events 2016

48

ESMO IO, Lausanne

Scientific Conferences Financial Reporting Investor Conferences Clinical Trials

EKF, Frankfurt

Q3

SITC US, New Harbour

December

Legend: ICIC SITC Society for Immunotherapy of Cancer | EKF Eigenkapitalforum

November

COMPANY PRESENTATION NOVEMBER 2016

www.mologen.com